Navigare Ventures

IntuiCell is a technology company focused on developing innovative brain intelligence solutions that leverage a unique recursive computing architecture. This architecture enables the company to tackle both tractable and intractable challenges using artificial intelligence. IntuiCell's technology can operate on existing hardware platforms or as standalone applications, requiring no external computational support. This adaptability allows various industries to enhance the functionality of consumer-level electronics, addressing a wide range of challenges and improving overall performance.

Repli5 is a company focused on advancing the development of autonomous vehicles by streamlining the creation of virtual three-dimensional environments. Its software tool automates the generation of complex simulation environments, which significantly reduces development time for autonomous systems. By providing the automotive industry with tailored solutions, Repli5 enables manufacturers to expedite the production of innovative vehicles, thereby accelerating the integration of advanced mobility solutions into the market. Through its technology, Repli5 aims to facilitate the rapid advancement of freight and haulage systems, contributing to the future of transportation.

SweGaN is a technology company specializing in the production of nitride-based high electron mobility transistor (HEMT) structures, primarily focusing on custom-made epitaxial wafers. The company's innovative GaN on SiC technology is designed to meet the demands of next-generation high-power and high-frequency devices, such as military radar systems and energy-efficient mobile base stations. By integrating advanced materials into their products, SweGaN aims to enhance energy efficiency and capacity for their clients, addressing the evolving challenges in the semiconductor industry. Founded by experts with extensive experience in the growth and characterization of GaN and SiC materials, SweGaN is currently in a phase of significant expansion and actively seeks skilled professionals in the field to join their team.

Arevo specializes in the development of biostimulants and plant nutrition products, primarily focusing on the cultivation of forest plants such as pine and spruce. The company's innovative technologies include liquid and granular amino acid fertilizers that enhance plant establishment and growth. Arevo's specialized fertilizers not only promote improved growth but also significantly impact plant survival and carbon sequestration. By fostering robust root systems, their products help make plants more stress-resistant, thereby simplifying the cultivation process for producers.

RiACT is a developer of robotic automation software focused on enhancing agile production systems. The company offers a universal operating system that serves as the interface between robotic hardware and intelligent robot applications. Its software features a real-time development platform, designed for both creators and users of flexible robot applications, and includes a visual drag-and-drop interface along with template-based coding. By providing these tools, RiACT enables users to maximize human potential and productivity within industrial environments.

Pixelgen Technologies is a company focused on advancing biomedical research and diagnostics through the development of innovative bio-analytical tools. Founded in 2020 and based in Sweden, Pixelgen Technologies creates novel analytical methods and products that provide researchers and drug developers with insights into the complexities of biological processes. By enhancing the understanding of biomedicine, the company aims to support improvements in health and contribute to the advancement of medical science.

AlixLabs specializes in nanostructure fabrication utilizing atomic layer etching (ALE) technology, which enables the production of nanostructures with sizes smaller than 20 nanometers. This damage-free etching process surpasses the resolution limits of traditional optical and electron beam lithography, making it suitable for advanced applications in nanoelectronics. AlixLabs focuses on providing innovative manufacturing techniques that allow for precise and efficient creation of extremely small structures without the need for complex nano-patterning methods. By enhancing the capabilities of semiconductor manufacturing, AlixLabs contributes to the advancement of transistor technology, particularly for sub-20 nm technology nodes.

TeraSi is a developer of advanced System-in-Package (SiP) technology that integrates multiple electronic components into a compact and efficient miniaturized package. The company specializes in creating hardware solutions that emphasize best-in-class performance, size, and weight. TeraSi's innovative approach combines ultra-low signal loss and precise functionality within a lightweight design, allowing clients to utilize scalable manufacturing processes. This technology supports the development of high-performance RF systems, positioning TeraSi at the forefront of wireless technology innovation and enabling advancements that will shape the future of electronic communication.

Retein is a water purification technology company focused on producing pure water at low energy costs. The firm utilizes advanced material recovery technology, specifically employing aquaporin proteins, to effectively remove pollutants such as microplastics and pharmaceutical residues from water. This innovative approach not only ensures the purification of water but also facilitates the sustainable recovery of valuable resources, promoting efficiency and cost-effectiveness for its clients. Retein aims to contribute to a resource-efficient and sustainable world through its cutting-edge solutions.

AlixLabs specializes in nanostructure fabrication utilizing atomic layer etching (ALE) technology, which enables the production of nanostructures with sizes smaller than 20 nanometers. This damage-free etching process surpasses the resolution limits of traditional optical and electron beam lithography, making it suitable for advanced applications in nanoelectronics. AlixLabs focuses on providing innovative manufacturing techniques that allow for precise and efficient creation of extremely small structures without the need for complex nano-patterning methods. By enhancing the capabilities of semiconductor manufacturing, AlixLabs contributes to the advancement of transistor technology, particularly for sub-20 nm technology nodes.

EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. It specializes in biocatalysis and cell-free synthetic biology, providing sustainable alternatives to traditional materials such as plastics, nylons, and rubbers. EnginZyme's innovative platform utilizes enzymes to facilitate the green manufacturing of products essential to various industries, including pharmaceuticals, food, chemicals, flavors, and fragrances. By replacing fossil-based manufacturing processes with its patented cell-free technology, the company aims to contribute to climate change mitigation and promote sustainable biomanufacturing practices. EnginZyme has garnered recognition as a Global Cleantech 100 company and has been acknowledged as a Technology Pioneer by the World Economic Forum, underscoring its commitment to advancing green chemistry across multiple sectors.

Pixelgen Technologies is a company focused on advancing biomedical research and diagnostics through the development of innovative bio-analytical tools. Founded in 2020 and based in Sweden, Pixelgen Technologies creates novel analytical methods and products that provide researchers and drug developers with insights into the complexities of biological processes. By enhancing the understanding of biomedicine, the company aims to support improvements in health and contribute to the advancement of medical science.

Rarity Bioscience is a biotechnology company that specializes in developing advanced molecular amplification technology for the detection of nucleic acid sequences. The company’s primary focus is on creating ultrasensitive multiplex assays capable of identifying small amounts of DNA sequence variants in biological samples, particularly in liquid biopsies. This innovative platform provides valuable tools for both research and clinical applications, enhancing the ability of physicians to detect rare genetic variations that may be critical for diagnosis and treatment. Through its technology, Rarity Bioscience aims to improve the precision and effectiveness of molecular diagnostics.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.

Repli5 is a company focused on advancing the development of autonomous vehicles by streamlining the creation of virtual three-dimensional environments. Its software tool automates the generation of complex simulation environments, which significantly reduces development time for autonomous systems. By providing the automotive industry with tailored solutions, Repli5 enables manufacturers to expedite the production of innovative vehicles, thereby accelerating the integration of advanced mobility solutions into the market. Through its technology, Repli5 aims to facilitate the rapid advancement of freight and haulage systems, contributing to the future of transportation.

Peafowl Plasmonics is a company focused on innovative solar cell technology that emphasizes efficiency, affordability, and sustainability. The firm has developed highly transparent plasmonic solar cells capable of absorbing light in various conditions, including harsh outdoor environments and low-illumination indoor settings. This versatility allows for the seamless integration of sensors directly into window glass, eliminating the need for wires or batteries. By enabling commercial partners and customers to reduce energy consumption and lower carbon emissions, Peafowl Plasmonics contributes to efforts aimed at minimizing corporate carbon footprints.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.